Posted on December 23rd, 2011 by Health News
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) reported the presentation of results from a phase 2 trial evaluating MLN8237, an investigational inhibitor of Aurora A kinase, in patients with aggressive B-cell and T-cell non-Hodgkin lymphoma (NHL)…
No Comments »
Filed under: Pharmacy News
Posted on December 17th, 2011 by Health News
The trial conducted by the Radiation Therapy Oncology Group (RTOG) shows the feasibility to deliver bevacizumab to the current chemoradiation standard without any apparent increased adverse side effects.
No Comments »
Filed under: Pharmacy News
Posted on December 16th, 2011 by Health News
Gynaecological cancer survival rates have improved in Eastern England following the reorganisation of services and multidisciplinary team working finds a new study published in the gynaecological oncology themed issue of BJOG: An International Journal of Obstetrics and Gynaecology…
No Comments »
Filed under: Women's Health
Posted on December 15th, 2011 by Health News
HPV DNA testing is better than cytology alone in preventing cervical cancer or detecting it early on for women over thirty, researchers reported in The Lancet Oncology. The authors explained, after reporting on the POBASCAM trial, that they now have compelling evidence in favour of routine HPV testing in national screening programs…
No Comments »
Filed under: Women's Health
Posted on December 8th, 2011 by Health News
ZIOPHARM Oncology, Inc. announced today that it has received an allowance from the European Patent Office for Patent Application No. 05 821 125.1, entitled “Salts of Isophosphoramide mustard and analogs thereof as anti-tumor agents” with claims directed to pharmaceutical compositions of a novel DNA cross-linker, including palifosfamide and their use in treating cancer.
No Comments »
Filed under: Pharmacy News
Posted on December 7th, 2011 by Health News
Cell Therapeutics, Inc. today announced that the U.S. Food and Drug Administration’s Division of Oncology Products 1 has notified CTI that CTI’s October 2011 resubmitted New Drug Application is considered a complete, Class 2 response to the FDA’s April 2010 complete response letter.
No Comments »
Filed under: Pharmacy News
Posted on December 1st, 2011 by Health News
Idera Pharmaceuticals, Inc. today announced that it has regained global rights to IMO-2055, an agonist of Toll-like Receptor (TLR) 9, as part of an agreed-upon termination of its oncology collaboration with Merck KGaA, Darmstadt, Germany.
No Comments »
Filed under: Pharmacy News
Posted on November 30th, 2011 by Health News
Neogenix Oncology, Inc. has announced that the company’s novel antibody NEO-101, which targets pancreatic and colorectal cancer cells, has been selected as one of Windhover’s 2011 Top 10 Projects to Watch.
No Comments »
Filed under: Pharmacy News
Posted on November 26th, 2011 by Health News
(MedPage Today) — The time has come for a fundamental shift in attitude toward cancer screening, with greater emphasis on absolute risks and the potential for harm associated with screening, according to a behavioral oncology researcher.
No Comments »
Filed under: General Health News
Posted on November 22nd, 2011 by Health News
ZIOPHARM Oncology, Inc. announced today the publication of a darinaparsin (Zinapar or ZIO-101) study in the PLoS ONE, an international, peer-reviewed, open-access, online publication of the Public Library of Science.
No Comments »
Filed under: Pharmacy News
